A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06505928
- Locations
- 🇲🇳
National cancer canter of Monglia, Ulaanbaatar, Mongolia
🇲🇳National Center for Communicable Diseases, Ulaanbaatar, Mongolia
Study of Hepalatide in Chronic Hepatitis D(CHD) Patients
Phase 2
Completed
- Conditions
- Chronic Hepatitis D Infection
- Interventions
- Drug: Hepalatide Placebo
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT05827146
- Locations
- 🇨🇳
The first hospital of Jilin University, Changchun, China
🇨🇳The first affiliated hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
🇲🇳the National cancer center of Mongolia, Ulaanbaatar, Mongolia
A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients
Phase 2
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Placebo of HepalatideDrug: Pegylated Interferon alfa 2a
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05244057
- Locations
- 🇨🇳
Shanghai Tong Ren Hospital, Shanghai, Shanghai, China
A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Registration Number
- NCT04662164
A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B
Phase 2
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: Hepalatide 4.2mgDrug: Hepalatide 2.1mgDrug: Hepalatide 6.3mgDrug: placebo 2.1mgDrug: Pegylated InterferonDrug: placebo 4.2mgDrug: placebo 6.3mg
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT04426968
- Locations
- 🇨🇳
Jilin Hepatobiliary Disease Hospital, Changchun, China
🇨🇳Shanghai Tongren Hospital, Shanghai, China
🇨🇳Chizhou People's Hospital, Chizhou, China
Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT03023787
- Locations
- 🇨🇳
302 Military Hospital, Beijing, China
Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2017-02-14
- Lead Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT02612506
- Locations
- 🇨🇳
302 Military Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath